These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11259835)

  • 1. Active secretion and enterocytic drug metabolism barriers to drug absorption.
    Wacher VJ; Salphati L; Benet LZ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):89-102. PubMed ID: 11259835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
    Zhang Y; Benet LZ
    Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
    Benet LZ; Izumi T; Zhang Y; Silverman JA; Wacher VJ
    J Control Release; 1999 Nov; 62(1-2):25-31. PubMed ID: 10518631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction of intestinal CYP3A4 and P-glycoprotein.
    Kivistö KT; Niemi M; Fromm MF
    Fundam Clin Pharmacol; 2004 Dec; 18(6):621-6. PubMed ID: 15548232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The drug efflux-metabolism alliance: biochemical aspects.
    Benet LZ; Cummins CL
    Adv Drug Deliv Rev; 2001 Oct; 50 Suppl 1():S3-11. PubMed ID: 11576692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
    Ito K; Kusuhara H; Sugiyama Y
    Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
    Murakami T; Bodor E; Bodor N
    Expert Opin Drug Metab Toxicol; 2021 May; 17(5):555-580. PubMed ID: 33703995
    [No Abstract]   [Full Text] [Related]  

  • 10. Intestinal efflux transporters and drug absorption.
    Murakami T; Takano M
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):923-39. PubMed ID: 18624680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine.
    Akazawa T; Yoshida S; Ohnishi S; Kanazu T; Kawai M; Takahashi K
    Drug Metab Dispos; 2018 Nov; 46(11):1497-1506. PubMed ID: 30135242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal drug transporters: in vivo function and clinical importance.
    Kunta JR; Sinko PJ
    Curr Drug Metab; 2004 Feb; 5(1):109-24. PubMed ID: 14965254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions.
    Zakeri-Milani P; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):859-71. PubMed ID: 24708201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
    Cummins CL; Jacobsen W; Benet LZ
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of expression/function of intestinal P-glycoprotein under disease states.
    Murakami T; Bodor E; Bodor N
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
    [No Abstract]   [Full Text] [Related]  

  • 16. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.
    Cao X; Gibbs ST; Fang L; Miller HA; Landowski CP; Shin HC; Lennernas H; Zhong Y; Amidon GL; Yu LX; Sun D
    Pharm Res; 2006 Aug; 23(8):1675-86. PubMed ID: 16841194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological role of P-glycoprotein in the intestinal epithelium.
    Van Asperen J; Van Tellingen O; Beijnen JH
    Pharmacol Res; 1998 Jun; 37(6):429-35. PubMed ID: 9695116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
    Zhang H; Yao M; Morrison RA; Chong S
    Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.